Free Breaking News

Experimental Drug: A Hope for Melanoma Patients

by skincancerexample.com

Last October 10, Dr. Georgina Long announced that the experimental melanoma drug helps control brain metastases and reduced the size of brain tumors. She gladly pronounced the success of the phase two trial of the oral drug to the congress of European Society for Medical Oncology (ESMO). Dr. Long also facilitated the first clinical trial of the melanoma medicine. It was the earliest achievement of the study. The third stage of the experiment will be held in July, next year.

Melanoma

Melanoma is a rare skin cancer. It is an abnormal production of melanin-producing cells. Melanin gives the human body its color. The onset of the disease is the excess discoloration in the skin. Sometimes, it is mistaken to be a mole. It may also start in the eyes or intestines. The mole-like appearance is easily distinguished by its irregular shape, uneven border, rapid growth and painful sensation. Melanoma is curable. It has the highest number of death cases among skin cancer.

Genetics and tanning beds, which emit ultraviolet rays are some of the causes of this condition. Excessive sun exposure, especially during the hottest part of the day can be the causative factor. The prognosis of the disease is good if detected and diagnosed early. The treatment focuses on the prevention of aggravating complications like brain metastasis or growth of tumors. The new experimental drug is a good innovation from the company since this disorder is resistant to therapy, especially in the latent stage. (insert)

Experimental Drug

GSK2118436 is the tentative research name provided by GlaxoSmithKline. Dr. Long used ten subjects with brain metastasis melanoma. Based on the outcome of the experiment, all the sample representatives had control of the spread of the cancerous cells in the brain. Fortunately, nine of them revealed a significant decrease of the tumor. The success of this drug was widely accepted.

The pharmaceutical company approved the third phase of the trial and re-tests its quality. There were also corporations that had the same results like Roche Pharmaceuticals and Bristol-Myers Squibb. In its final screening, PLX4032 and Ipilimumab were the treatments which showed qualified effect. The new experimental drug is expected to show the same relevant upshot with its late-stage development.

Hope For Melanoma Patients

Based on American Cancer Society, in the year 2010, about 68,130 new melanomas cases will be diagnosed in the United States. There will be about 38,870 men affected and 29,260 in women. It is common to young women and older white men. The statistics showed a bigger possibility on the increasing incidence of melanoma.

The wide researches conducted by several scientists and physicians can alleviate the consequences of the disorder. The newest experimental drug is another hope for the reduction of the severity of the disease. The simplest strategy to detect or prevent such an illness is health awareness. Medical consultation is also advised by the US Food and Drug Administration (FDA).

References:

http://www.reuters.com/article/idUSTRE6990MJ20101010

http://www.cancer.gov/cancertopics/types/melanoma

November 5, 2010 - Posted by ambra | Health | Experimental Drug, Hope For Melanoma Patients, Melanoma, New Experimental Drug